SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

TASP0277308

Item No. 11340

CAS Registry No.: 945725-50-8
Formal Name: 3,4-dichloro-N-[(1R)-1-[4-ethyl-5-[3-(4-methyl-1-piperazinyl) phenoxy]-4H-1,2,4-triazol-3-yl] ethyl]-benzenesulfonamide
MF: $C_{23}H_{28}Cl_2N_6O_3S$
FW: 539.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TASP0277308 is supplied as a solid. A stock solution may be made by dissolving the TASP0277308 in the solvent of choice, which should be purged with an inert gas. TASP0277308 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in methanol.

Description

TASP0277308 is a sphingosine-1-phosphate receptor 1 ($S1P_1$) antagonist (IC_{50} = 4.2 nM).[1] It is selective for $S1P_1$ over $S1P_3$, $S1P_4$, and $S1P_5$ (IC_{50}s = >10,000, >10,000, and 8,756 nM, respectively). TASP0277308 inhibits S1P-induced [^{35}S]GTPγS binding and forskolin-induced cAMP production in HEK293 cells expressing human $S1P_1$ (IC_{50}s = 7.8 and 4.3 nM, respectively). It inhibits S1P-induced migration of CHO cells expressing human $S1P_1$ (IC_{50} = 18 nM). *In vivo*, TASP0277308 (100 mg/kg) induces lymphopenia in mice. It reduces bone erosion in a mouse model of collagen-induced arthritis. Intrathecal administration of TASP0277308 (3 or 10 nmol/animal) reduces flinching and guarding behaviors in a mouse model of cancer-induced bone pain.[2]

References

1. Fujii, Y., Hirayama, T., Ohtake, H., *et al.* Amelioration of collagen-induced arthritis by a novel $S1P_1$ antagonist with immunomodulatory activities. *J. Immunol.* **188(1)**, 206-215 (2012).
2. Grenald, S.A., Doyle, T.M., Zhang, H., *et al.* Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation. *Pain* **158(9)**, 1733-1742 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM